Table 2.

Treatment-emergent AEs occurring in >10% of patients in the safety analysis set by CTCAE grade.

	All patients and doses (N = 57)		160 mg BD melanoma (N = 6)		240 mg BD melanoma (N = 9)
	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grader ≥3
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Patients with any AE	57 (100%)	28 (49.1%)	6 (100%)	4 (67%)	5 (56%)	5 (56%)
Anemia	27 (47%)	13 (23%)	5 (83.3%)	3 (50%)	2 (22.2%)	2 (22.2%)
Neutropenia and neutrophil count decreased	24 (42%)	17 (30%)	4 (83.3%)	4 (67%)	5 (56%)	5 (56%)
Anorexia	17 (30%)	0	2 (33.3%)	0	2 (22.2%)	0
Nausea	17 (30%)	1 (2%)	2 (33.3%)	0	3 (33.3%)	0
Alopecia	15 (26%)	0	2 (33.3%)	0	0	0
Fatigue	10 (17%)	0	1 (17%)	0	3 (33.3%)	0
Platelet count decreased and thrombocytopenia	7 (12%)	5 (9%)	1 (17%)	1 (17%)	4 (44.4%)	3 (33.3%)
Pruritus	7 (12%)	0	2 (33.3%)	0	4 (44.4)	0
Vomiting	7 (12%)	1 (2%)	1 (17%)	0	2 (22.2%)	0
Rash	7 (12%)	0	2 (33.3%)	0	1 (11.1%)	0